

Date: 30-05-2024

To, Cooperate Relation Department The BSE LIMITED 1st Floor, Phiroze leejeebhoy Towers, Dalal Street, Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Year Ended on 31st March, 2024.

Please find enclosed herewith Newspaper clippings of Audited Financial Results for the quarter and year ended on 31st March, 2024 published in FREE PRESS JOURNAL and NAVSHAKTI on 30th May, 2024 in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on 29th May, 2024.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,

For Colinz Laboratories Ltd.,

Dr. Mani L. S.

Director & Company Secretary

Din No: 00825886

* FREE PRESS JOURNAL *

Dt- 80/5/2029

COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospita!, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO: L24200MH1986PLC041128)

EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2024

	Kala a com a transfer from the commence of				(Rs. In Lacs	
S. No.	Particulars	QUARTER ENDED			YEAR ENDED	
		Audited	Un-Audited	Audited	Audited	Audited
		31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23
1	Revenue from Operations	173.64	176.23	176.34	730.46	732.70
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	18.96	14.63	15.78	65.03	59.98
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	18.96	14.63	15.78	65.03	59.98
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	13.60	10.63	12.79	48.67	45.74
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income(Net of Tax).	19.78	21.93	9.98	80.97	45.17
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	251.91	251.91	251.91
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)				14,013 E	ora inst
	1) Basic	0.54	0.42	0.51	1.93	1.82
	2) Diluted	0.54	0.42	0.51	1.93	1.82

NOTES

- The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 29th May, 2024.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cil.in.
- The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit
 opinion on the same.
- 4) Previous figures have been regrouped/rearranged/reclassified, wherever necessary.

MUMBAI. 29th May, 2024. NAME OF STREET

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO: L24200MH1986PLC041128 Dr. MANI L. S.

(Chairman of the Meeting)

For COLINZ LABORATORIES LTD.

Director

* NAY-SHAKTI *

04. 30/5/2024

१२ नव अशक्ति। मुंबई, गुरुवार, ३० मे २०२४

COLINZ LABORATORIES LIN

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO : L24200MH1986PLC041128)

EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2024

AND YEAR LINDED O.								
	Consideration of Consideration	QUARTER ENDED			YEAR ENDED			
S. No.	Particulars	Audited	Un-Audited	Audited	Audited	Audited		
		31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23		
1	Revenue from Operations	173.64	176.23	176.34	730.46	732.70		
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	18.96	14.63	15.78	65.03	59.98		
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	18.96	14.63	15.78	65.03	59.98		
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	13.60	10.63	12.79	48.67	45.74		
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	19.78	21.93	9.98		45.17		
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	251.91	251.91	251.91		
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.) 1) Basic 2) Diluted	0.5						

NOTES :-

- 1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 29th May, 2024.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at <u>www.bseindia.com</u> and on the Company's website at <u>www.findoc-cll.in</u>.
- The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.
- Previous figures have been regrouped/ rearranged / reclassified, wherever necessary.

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO: L24200MH1986PLC041128

MUMBAI. 29th May, 2024.

Dr. MANI L. S. (Chairman of the Meeting)

INZ LABORATORIES LTD. For

Director